# Beta-Blockers in Takotsubo Syndrome Study

Study · id `cardio:ct-nct06509074` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06509074](<https://clinicaltrials.gov/study/NCT06509074>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06509074

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06509074. Randomized; single masking; primary purpose treatment. Start 2024-08 (anticipated); primary completion 2025-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06509074, source copy `cardio:ctgov-nct06509074-2024-08-26`, retrieved 2026-10-26)
- Planned start: 2024-08 (anticipated) (ClinicalTrials.gov record NCT06509074, source copy `cardio:ctgov-nct06509074-2024-08-26`, retrieved 2026-10-26)
- Primary completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT06509074, source copy `cardio:ctgov-nct06509074-2024-08-26`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06509074, source copy `cardio:ctgov-nct06509074-2024-08-26`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT06509074, source copy `cardio:ctgov-nct06509074-2024-08-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06509074-2024-08-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Beta-Blockers in Takotsubo Syndrome Study
- Acronym: β-Tako
- Condition: Takotsubo Cardiomyopathy
- Condition: Beta-blockers
- Condition: Echocardiography
- Condition: Left Ventricular Function
- Intervention (Drug): Beta blocker
- Lead sponsor: Spanish Society of Cardiology
- Lead sponsor class: OTHER
- Collaborator: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: Spanish Society of Cardiology (`cardio:org-spanish-society-of-cardiology`)

## Provenance

Content hash: 1b0a7bda24916f30679841ab1c30c501280aa1c796b4a192cae292884adc93a3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
